EU Evaluation Of Orphan & Pediatric Legislation Nears Completion
Focus Is On Incentives & Access As Needs Remain Unmet
Spring 2020 should see the publication of a working document by the European Commission on how to improve the operation of the EU legislation on orphan and pediatric medicines. The commission has asked for more input from member state experts.
You may also be interested in...
Requests from sponsors for orphan drug status in the EU are showing a downward trend. It is not yet clear why, but a forthcoming report from the European Commission may provide some answers.
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.
A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.